MX2023007945A - Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r. - Google Patents

Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.

Info

Publication number
MX2023007945A
MX2023007945A MX2023007945A MX2023007945A MX2023007945A MX 2023007945 A MX2023007945 A MX 2023007945A MX 2023007945 A MX2023007945 A MX 2023007945A MX 2023007945 A MX2023007945 A MX 2023007945A MX 2023007945 A MX2023007945 A MX 2023007945A
Authority
MX
Mexico
Prior art keywords
peanut
antagonist
administering
methods
enhancing
Prior art date
Application number
MX2023007945A
Other languages
English (en)
Spanish (es)
Inventor
Allen Radin
Jamie M Orengo
Marcella Ruddy
Heribert Staudinger
Qiufan Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023007945A publication Critical patent/MX2023007945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023007945A 2021-01-08 2022-01-07 Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r. MX2023007945A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135238P 2021-01-08 2021-01-08
EP21315241 2021-11-10
PCT/US2022/011643 WO2022150605A1 (en) 2021-01-08 2022-01-07 Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
MX2023007945A true MX2023007945A (es) 2023-09-21

Family

ID=80034850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007945A MX2023007945A (es) 2021-01-08 2022-01-07 Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.

Country Status (9)

Country Link
US (1) US20220220211A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274609A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502471A (cg-RX-API-DMAC7.html)
KR (1) KR20230130681A (cg-RX-API-DMAC7.html)
AU (1) AU2022206434A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204515A1 (cg-RX-API-DMAC7.html)
IL (1) IL304240A (cg-RX-API-DMAC7.html)
MX (1) MX2023007945A (cg-RX-API-DMAC7.html)
WO (1) WO2022150605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
EP4406975A3 (en) * 2018-06-14 2024-11-13 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US11504426B2 (en) * 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Also Published As

Publication number Publication date
JP2024502471A (ja) 2024-01-19
KR20230130681A (ko) 2023-09-12
US20220220211A1 (en) 2022-07-14
CA3204515A1 (en) 2022-07-14
EP4274609A1 (en) 2023-11-15
AU2022206434A1 (en) 2023-08-24
WO2022150605A1 (en) 2022-07-14
IL304240A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
SG11202113312VA (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
CY1124095T1 (el) Μεθοδοι για την ενισχυση της ειδικης ανοσοθεραπειας εναντι αλλεργιογονου με χορηγηση αναστολεα του ιl-4r
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
IL304240A (en) Methods for treating peanut allergy and improving immunotherapy for a specific peanut allergen by administering an il-4r antagonist
JOP20200305A1 (ar) أجسام مضادة لـ entpd2، توليفة علاجات، وطرق استخدام الأجسام المضادة وتوليفة العلاجات
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
ZA201805295B (en) Methods for enhancing efficacy of a vaccine by administering an il¿4r antagonist
PH12014500784B1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2007056539A3 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
MD20170031A2 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
ECSP088529A (es) Anticuerpos anti mn y métodos para su utilización
MX2021009186A (es) Captadores biespecificos de linfocitos t codificados por adn que se dirigen a antigenos de cancer y metodos de uso en tratamientos contra cancer.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
ZA201806397B (en) Humanized anti clever-1 antibodies and their use
EP4653462A3 (en) Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
WO2013009521A3 (en) Methods and compositions for treating asthma using anti-il-13 antibodies
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
MX2022000649A (es) Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
GB201206070D0 (en) Clostridium difficile antigens
HK1201175A1 (en) Antigen presenting cancer vaccine with gamma interferon
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.